Loading stock analysis…
Evidence Synthesis
Last synthesized: 8 Jul 2026, 02:07
Evidence Synthesis
AARTIPHARM shifted into the green zone, with the 54.12% representing a 17.5% increase in the past quarter.
The company's revenue growth accelerated to from -30.8% in the previous quarter. However, the daily volume moved from 243514 shares to 121102 shares, a decline of shares. The close price also declined by INR from 705.35 INR.
Source observations behind the synthesis narrative.
| Metric | Value | Previous Value | Trend |
|---|---|---|---|
| GROSS_MARGIN | 54.12 % | 17.5 | ▲ |
| MARGINAL_OPERATING_LEVERAGE | 17.5 % | 9.6 | ▲ |
| REVENUE_GROWTH_YOY | 3.3 % | -30.8 | ▲ |
| PRICE_CHANGE_PERCENT | -0.829 % | — | - |
| DAILY_VOLUME | 1,21,102 shares | 2,43,514 | ▼ |
| CLOSE_PRICE | 699.5 INR | 705.35 | ▼ |
| NEWS_SENTIMENT_SCORE | 0 score | — | - |
| ANALYST_STRONG_BUY_COUNT | 0 count | 0 | - |
| TARGET_PRICE_PREMIUM | 5.79 % | — | - |